AlphaMa

Executive Summary

AlphaMa Biotechnology is a Chinese AI-driven drug discovery company that leverages its proprietary DEL-AI platform, integrating artificial intelligence with DNA-encoded library (DEL) technology. Focused on oncology and metabolic diseases, AlphaMa aims to accelerate early-stage drug discovery by developing computational models that identify and optimize active molecules for clinically relevant targets. Founded in 2019 and headquartered in Suzhou, the company operates as a private platform-stage entity with a lean team of 10-50 employees. While still in its early growth phase, AlphaMa's innovative approach positions it within the rapidly evolving AI drug discovery landscape, offering potential for efficient hit identification and lead optimization. The company's progress will depend on its ability to secure partnerships and advance internal programs towards preclinical validation.

Upcoming Catalysts (preview)

• TBDStrategic Partnership with Pharmaceutical Company40% success
• TBDAdvancement of Internal Oncology Program to Preclinical Stage30% success
• TBDSeries A Financing Round50% success